الفهرس 
Feasibility of the gene sequencing test in Egyptian patients with early Stage breast cancer
AbstractOnly 14 pages are availabe for public view
 |  | from | 154 |  |  |
| | | from | 154 | | |
Abstract
Aim: Assessment the feasibility of Next Generation Sequencing (NGS) as a new prognostic multigene assay for the Egyptian patients with early stage breast cancer as a predictor of benefit from adjuvant chemotherapy. Patients and methods: Ten female patients with early stage breast cancer were enrolled in the study. They were treated according to the Multi-Disciplinary Team decision. The clinical and histological data of them logged into (Predict) web based application to detect their 10 years survival benefits of chemotherapy.Tissue sample of the tumor of each of the ten patients was submitted to Next Generation Sequencing test by the cancer biology department to detect the genetic risk of local and distance recurrence. The study group was followed up for 3 years to interpret the decision taken by the (MDT) to the results obtained by predict and NGS. Results: Ten female patients ranged from 36 to 69 years old were enrolled in the study according to the selection criteria all of them had Conservative Breast Surgery as decided by MDT and decided for no chemotherapy. By use of predict application 3 patients were found not to benefit from chemotherapy while the other 7 would make a survival benefits. By application of NGS there were 5 patients with high risk and 5 with low risk for local and distance recurrence. During the initial follow up period 2 cases developed local recurrence and were found to be from the high risk groups in both predict and NGS.These two cases underwent modified radical mastectomy and enrolled to receive chemotherapy and still surviving with no local or distant disease